Sign In
Buy OCUL
$8.35
+0.0400 (+0.481%)
At Close: Jun 03, 2026
Satsuma Migraine Failure, And Other News: The Good, Bad And Ugly Of Biopharma
05:48am, Monday, 14'th Sep 2020
Satsuma reports disappointing top-line data for Phase 3 trial. Ocular Therapeutix begins dosing for Dextenza study.
Ocular - Small-Cap Pharmaceutical Growth Story
01:05pm, Wednesday, 02'nd Sep 2020
The newest program, OTX-DED, is possibly the next one to enter the market. Rebate of work done with 0356T might drive adoption by new clinics.
Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates
12:45pm, Friday, 07'th Aug 2020
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -6.25% and -1.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix: Q2 Earnings Insights
11:34am, Friday, 07'th Aug 2020
Shares of Ocular Therapeutix (NASDAQ:OCUL) moved higher by 1% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share were down 12.28% year over year to ($0.64
Ocular Therapeutix™ Reports Second Quarter 2020 Financial Results and Business Update
11:15am, Friday, 07'th Aug 2020
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, t
Ocular Therapeutix™ Reports Second Quarter 2020 Financial Results and Business Update
12:00am, Friday, 07'th Aug 2020
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative the
Earnings Outlook for Ocular Therapeutix
08:08pm, Thursday, 06'th Aug 2020
Ocular Therapeutix (NASDAQ: OCUL) announces its next round of earnings this Friday, August 07. Here is Benzinga's look at Ocular Therapeutix's Q2 earnings report.Earnings and Revenue Sell-side analyst
Should You Buy Ocular Therapeutix (OCUL) Ahead of Earnings?
12:37pm, Thursday, 06'th Aug 2020
Ocular Therapeutix (OCUL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) Path To Profitability
07:30pm, Wednesday, 05'th Aug 2020
Ocular Therapeutix, Inc.'s (NASDAQ:OCUL): Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the...
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
12:00am, Sunday, 02'nd Aug 2020
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
Ocular Therapeutix™ To Report Second Quarter 2020 Financial Results
11:00am, Friday, 31'st Jul 2020
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, t
Ocular Therapeutix (OCUL) Expected to Beat Earnings Estimates: Should You Buy?
04:33pm, Wednesday, 29'th Jul 2020
Ocular Therapeutix (OCUL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today
The Daily Biotech Pulse: Midatech Shelves Sale Plan, G1 Therapeutics Out-Licenses, Entera Bio Jumps On Survey Results
12:00am, Thursday, 23'rd Jul 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 22)
ABIOMED, Inc. (NASDAQ: ABMD)
Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO)
Bio-Rad Laboratories,...
Ocular Therapeutix Presents at the 12th Annual Ophthalmology Innovation Summit (OIS)
11:30am, Friday, 17'th Jul 2020
Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, part
